T1	Participants 56 93	postmenopausal breast cancer patients
T2	Participants 432 509	metastatic breast cancer patients with previous exposure to endocrine therapy
T3	Participants 2074 2176	Patients whose tumor expresses p-p70S6K, as a marker of downstream PI3K and/or MAPK pathway activation
